Vertex Pharmaceuticals (BSP:VRTX34) DeferredTaxAndRevenue: R$0 Mil (As of Mar. 2026)


BSP:VRTX34 Vertex Pharmaceuticals Inc BSP:VRTX34
86 GF Score
Price R$621.43
GF Value R$646.37
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals DeferredTaxAndRevenue?

Vertex Pharmaceuticals BSP:VRTX34 -0.61% 86 DeferredTaxAndRevenue is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:VRTX34 with a GF Score™ of 86/100 and a GF Value™ of R$646.37 (Fairly Valued). The stock has 5 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Vertex Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was R$0 Mil.

Vertex Pharmaceuticals DeferredTaxAndRevenue Related Terms

Vertex Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals DeferredTaxAndRevenue Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 970.95 837.17 834.44 1,261.69 937.29

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 937.29 0.00
BSP:VRTX34
86GF Score
Vertex Pharmaceuticals Inc BSP:VRTX34
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of R$0 Mil mean?
Vertex Pharmaceuticals (BSP:VRTX34) has a DeferredTaxAndRevenue of R$0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Vertex Pharmaceuticals.
Is Vertex Pharmaceuticals' DeferredTaxAndRevenue too high?
Vertex Pharmaceuticals' current DeferredTaxAndRevenue is R$0 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' DeferredTaxAndRevenue compare to REGN and ALNY?
Vertex Pharmaceuticals' DeferredTaxAndRevenue of R$0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Vertex Pharmaceuticals. Vertex Pharmaceuticals's current DeferredTaxAndRevenue is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (BSP:VRTX34) is currently considered Fairly Valued. The stock's GF Value™ is R$646.37, compared to a current price of R$621.43 — trading 3.9% below its estimated fair value. The current DeferredTaxAndRevenue is R$0 Mil. Vertex Pharmaceuticals' overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Vertex Pharmaceuticals (BSP:VRTX34), the current DeferredTaxAndRevenue is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of R$621.43 is trading 3.9% below its estimated GF Value™ of R$646.37. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for BSP:VRTX34:

  • DeferredTaxAndRevenue: R$0 Mil
  • GF Value™: R$646.37 vs. price of R$621.43 (3.9% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score

Get the complete analysis for BSP:VRTX34

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$621.43
Price
R$646.37
GF Value